These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 16842188)

  • 1. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
    Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
    Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
    Rawat R; Whitty A; Tonge PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
    Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
    da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
    J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates.
    Basso LA; Zheng R; Musser JM; Jacobs WR; Blanchard JS
    J Infect Dis; 1998 Sep; 178(3):769-75. PubMed ID: 9728546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
    Parikh SL; Xiao G; Tonge PJ
    Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
    Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
    Vilchèze C; Jacobs WR
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
    Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
    Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents.
    Oliveira JS; Vasconcelos IB; Moreira IS; Santos DS; Basso LA
    Curr Drug Targets; 2007 Mar; 8(3):399-411. PubMed ID: 17348833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.